shield test (Guardant Health)
86
Structured Review
Guardant Health
shield test
Shield Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shield+test/shield+test/pmc13012238-165-3-5
Average 86 stars, based on 1 article reviews
Shield Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shield+test/shield+test/pmc13012238-165-3-5
Average 86 stars, based on 1 article reviews
shield test - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer Article Snippet: For example, the Article Title: A Blood-Based Test for Colorectal Cancer Screening Article Snippet: The ECLIPSE trial, a prospective cohort study that was sponsored by Screening Assay:Article Title: Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies Article Snippet: The updated multitarget stool DNA test (Cologuard Plus) demonstrated a sensitivity of 93.9% (95% CI, 87.1–97.7) for CRC and 43.4% (95% CI, 41.3–45.6) for advanced precancerous lesions, with a specificity of 90.6% (95% CI, 90.1–91.0) in asymptomatic adults ( ). .. The Article Title: Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies. Article Snippet: The updated multitarget stool DNA test (Cologuard Plus) demonstrated a sensitivity of 93.9% (95% CI, 87.1–97.7) for CRC and 43.4% (95% CI, 41.3–45.6) for advanced precancerous lesions, with a specificity of 90.6% (95% CI, 90.1–91.0) in asymptomatic adults (69). .. The Methylation:Article Title: Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies Article Snippet: The updated multitarget stool DNA test (Cologuard Plus) demonstrated a sensitivity of 93.9% (95% CI, 87.1–97.7) for CRC and 43.4% (95% CI, 41.3–45.6) for advanced precancerous lesions, with a specificity of 90.6% (95% CI, 90.1–91.0) in asymptomatic adults ( ). .. The Article Title: Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies. Article Snippet: The updated multitarget stool DNA test (Cologuard Plus) demonstrated a sensitivity of 93.9% (95% CI, 87.1–97.7) for CRC and 43.4% (95% CI, 41.3–45.6) for advanced precancerous lesions, with a specificity of 90.6% (95% CI, 90.1–91.0) in asymptomatic adults (69). .. The |